NAD+
Evidence: CMitochondrial / Cellular Aging
Evidence Snapshot
What this grade covers
C for limited direct human pharmacology, short-duration infusion studies, one small disease-specific randomized trial, and NAD+-specific FDA sterile-compounding safety evidence; D or lower for general wellness, anti-aging, performance, addiction treatment, broad cardiovascular benefit, chronic use, and long-term safety because adequately powered, replicated, long-duration controlled evidence is absent.
Regulatory Context
No FDA-approved direct NAD+ injection exists for anti-aging, energy, recovery, addiction, cognition, or general wellness. FDA has warned that food-grade NAD+ is unsuitable for sterile compounding without proper processing and has documented adverse-event reports and 2026 warning letters involving compounded NAD+ injectables.
Research Takeaway
Nicotinamide adenine dinucleotide (NAD+) is a vitamin B3-derived redox coenzyme and a substrate for enzymes including sirtuins, PARPs, and CD38-related pathways. NAD+ is not a peptide.
See all 8 evidence claims →Quick Summary
NAD+ (nicotinamide adenine dinucleotide) is an essential cellular redox coenzyme, not a peptide. It participates in cellular energy metabolism and enzyme signaling -- including sirtuins, PARPs, and CD38-related pathways -- but the clinical effects of directly injecting or infusing NAD+ remain incompletely established. Evidence that precursors such as NR or NMN raise NAD-related biomarkers does not prove that direct NAD+ injection produces the same effects or meaningful health outcomes.
Mechanism & Research Overview
NAD+ (nicotinamide adenine dinucleotide) is an essential cellular redox coenzyme, not a peptide. It participates in cellular energy metabolism and enzyme signaling -- including sirtuins, PARPs, and CD38-related pathways -- but the clinical effects of directly injecting or infusing NAD+ remain incompletely established. Evidence that precursors such as NR or NMN raise NAD-related biomarkers does not prove that direct NAD+ injection produces the same effects or meaningful health outcomes.
Evidence Grade Breakdown
A single letter grade can't capture how evidence quality differs across approved use, off-label use, and unsupported claims. The categories below break that down -- none of them grade this compound "overall."
Overall Research Grade
Direct human NAD+ evidence includes a small controlled metabolome pilot, a retrospective NAD+ versus NR tolerability study, a substance-use-disorder pilot, and one small disease-specific randomized cardiac study. These studies provide limited pharmacology, tolerability, and hypothesis-generating clinical information, while FDA material provides specific sterile-compounding and endotoxin-risk context. The evidence does not establish general wellness, anti-aging, performance, addiction-treatment, broad cardiovascular, or long-term clinical benefits.
CDirect Human Clinical Evidence
Show detail
Direct Human Clinical Evidence
Several small human studies evaluate direct intravenous NAD+, including a controlled six-hour metabolome pilot, a retrospective NAD+ versus NR tolerability study, a substance-use-disorder pilot, and one short disease-specific randomized cardiac study. Sample sizes are limited, exposure is short, and independent replication is absent.
CPharmacology and Mechanistic Evidence
Show detail
Pharmacology and Mechanistic Evidence
The controlled metabolome pilot demonstrates measurable plasma and urine NAD+-related changes during a six-hour infusion. This establishes short-term pharmacologic activity but does not establish anti-aging, energy, cognitive, addiction-treatment, performance, or disease benefit.
C/DSafety and Tolerability Evidence
Show detail
Safety and Tolerability Evidence
Short human studies and a retrospective commercial-setting comparison provide limited tolerability information. FDA has reported severe reactions consistent with excessive endotoxin exposure from improperly processed material used for sterile NAD+ compounding. Long-term clinical safety and route-specific safety outside the studied settings remain unestablished.
FApproved Clinical Indications
Show detail
Approved Clinical Indications
No FDA-approved NAD+ injectable product or approved general wellness, anti-aging, performance, addiction-treatment, or cardiovascular indication is established by the reviewed evidence.
DDisease-Specific and Off-Label Outcomes
Show detail
Disease-Specific and Off-Label Outcomes
One short randomized single-center study in ischemic cardiomyopathy reported a modest cardiac finding, but secondary outcomes were largely nonsignificant, the result has not been independently replicated, and it cannot support general cardiovascular or wellness claims.
DBiohacking, Wellness, and Anti-Aging Claims
Show detail
Biohacking, Wellness, and Anti-Aging Claims
The reviewed evidence does not establish broad anti-aging, energy, performance, cognitive, recovery, or general wellness benefit from direct NAD+ infusion. Evidence involving NADH, NR, NMN, nicotinamide, niacin, or oral precursors must not be treated as interchangeable with direct intravenous NAD+ evidence.
Evidence reviewed
- Randomized human trials
- 1
- Controlled human trials
- 2
- Observational human studies
- 1
- Systematic reviews
- 1
- Regulatory documents
- 1
- Primary sources reviewed
- 5 of 9
Study counts describe the reviewed evidence base. They do not independently determine evidence quality.
How MitoCore grades evidence
Grade definitions
- A
- Strong and directly applicable evidence, generally including regulatory support or multiple high-quality replicated human trials for the exact claim and population.
- A-
- Strong human evidence with limited uncertainty, narrower applicability, or incomplete replication.
- B+
- Moderately strong evidence with meaningful human support but important scope, duration, safety, or generalizability limitations.
- B
- Credible evidence with notable uncertainty, limited replication, or mixed results.
- C
- Preliminary or inconsistent evidence, usually limited human data or strong indirect evidence.
- D
- Weak, indirect, population-limited, or largely unsupported evidence for the specific use being graded.
- F
- No credible supporting evidence, evidence contradicting the claim, or claims based primarily on speculation or marketing.
Confidence definitions
- High
- The evidence classification is unlikely to change substantially with ordinary additional research.
- Moderate
- The classification is reasonably supported but could change with additional high-quality evidence.
- Low
- The evidence base is sparse, indirect, inconsistent, or dependent on uncertain assumptions.
- Very Low
- The evidence base is extremely limited, speculative, or unsuitable for firm conclusions.
Scope
The grade evaluates the evidence supporting the specific category or claim. A grade does not evaluate product purity, supplier quality, personal suitability, treatment appropriateness, individual outcomes, legality, or medical safety for a specific person.
These grades and confidence levels describe the research evidence itself. They are not medical recommendations, and they do not evaluate any specific product, supplier, or individual's situation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Nicotinamide adenine dinucleotide (NAD+) is a vitamin B3-derived redox coenzyme and a substrate for enzymes including sirtuins, PARPs, and CD38-related pathways. NAD+ is not a peptide.
Sources: NAD+ Anti-aging and Wellness Evidence (2026 Review)
Supported
No FDA-approved direct NAD+ injectable indication for anti-aging, energy, recovery, addiction treatment, cognitive enhancement, or general wellness was identified. FDA has warned compounders that food-grade NAD+ is not suitable for sterile compounding without appropriate processing because of microbial and endotoxin risk.
Supported
FDA received reports after NAD+ injectable products of severe chills, shaking, vomiting, and fatigue, with some patients requiring medical treatment. FDA stated that these reactions were consistent with excessive endotoxin levels associated with improperly processed material used for sterile compounding. These quality-related events do not establish that pure NAD+ itself caused every reaction.
Supported
A 2019 pilot study included eight NAD+ infusion participants and three controls. It evaluated plasma and urine metabolism during a six-hour infusion and was not designed to prove anti-aging, energy, addiction, cognitive, or disease benefit.
Sources: Direct IV NAD+ Metabolome Pilot
Supported
A 2026 retrospective real-world pilot found that commercial NAD+ IV use remained poorly studied and reported tolerability problems during infusion; the authors called for adequately powered randomized placebo-controlled trials.
Sources: NAD+ Versus NR IV Tolerability
Supported
A 2025 randomized single-center study in ischemic cardiomyopathy reported a modest improvement in left-ventricular ejection fraction after seven days of low-dose IV NAD+ alongside standard therapy. Secondary clinical outcomes were mostly nonsignificant trends. The result requires independent replication and cannot support general heart-health or wellness claims.
Sources: IV NAD+ in Ischemic Cardiomyopathy
Supported
Human trials show that NR and NMN can increase measured NAD-related metabolites under some conditions, but clinical outcome benefits are inconsistent. Evidence for a precursor cannot be transferred automatically to direct NAD+ injection, and NAD+, NADH, NR, NMN, nicotinamide, and niacin must not be treated as interchangeable.
Sources: NAD+ Anti-aging and Wellness Evidence (2026 Review)
Supported
No general FDA-approved wellness dosing exists for direct NAD+ injection or infusion. Published and registered studies use heterogeneous routes, infusion rates, doses, durations, and populations that must not be converted into IV-clinic protocols, subcutaneous regimens, insulin-syringe units, loading phases, addiction-detox schedules, anti-aging cycles, or combinations with glutathione, vitamins, SS-31, MOTS-c, or Humanin. Claims that NAD+ enters cells directly, repairs DNA, detoxifies, or reverses aging must not be stated as clinical outcomes.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Subjective energy response is inconsistent and uncertain.Safety Consideration
Rapid IV exposure is commonly associated anecdotally with flushing, chest tightness sensations, nausea, cramping, anxiety-like discomfort, or headache, depending on context.Safety Consideration
Long-term benefit claims for anti-aging or performance are not established.Safety Consideration
NAD+ biology is complex; raising NAD-related pathways does not automatically translate to clinical benefit.Safety Consideration
Product quality, sterility, storage, and route-specific safety vary widely outside regulated medical settings.Safety Consideration
FDA has warned that food-grade NAD+ is not suitable for sterile compounding without appropriate processing because of microbial and endotoxin risk; reported reactions after NAD+ injectable products (severe chills, shaking, vomiting, fatigue) were consistent with excessive endotoxin levels, with some patients requiring medical treatment.Safety Consideration
A single randomized study in ischemic cardiomyopathy reported a modest cardiac finding after seven days of IV NAD+, but the disease-specific result has not been independently replicated and does not establish cardiovascular safety or benefit for general wellness use.
Research Areas Being Studied
Research areas discussed on this page reflect the Mitochondrial / Cellular Aging category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- NAD+ Versus NR IV Tolerability (2026):
- IV NAD+ in Ischemic Cardiomyopathy (2025):
- NAD+ infusion pilot in substance use disorder (2022): Suggests rationale for further trials; not broad proof of wellness claims.
- Direct IV NAD+ Metabolome Pilot (2019):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| NAD+ Versus NR IV Tolerability | 2026 | 2026 retrospective real-world pilot: commercial NAD+ IV use remained poorly studied and reported tolerability problems during infusion. Authors called for adequately powered randomized placebo-controlled trials. | |||
| IV NAD+ in Ischemic Cardiomyopathy | 2025 | 2025 randomized single-center study in ischemic cardiomyopathy: modest improvement in left-ventricular ejection fraction after seven days of low-dose IV NAD+ alongside standard therapy. Secondary clinical outcomes mostly nonsignificant trends. Requires independent replication; cannot support general heart-health or wellness claims.
| |||
| NAD+ infusion pilot in substance use disorder | 2022 | Pilot study | SUD context — Suggests rationale for further trials; not broad proof of wellness claims. | Human data; interpret within the studied population, dose, duration, and endpoints. Review full paper for adverse events and exclusions. | |
| Direct IV NAD+ Metabolome Pilot | 2019 | 8 NAD+ infusion participants, 3 controls | 2019 pilot study evaluating plasma and urine metabolism during a six-hour NAD+ infusion. Not designed to prove anti-aging, energy, addiction, cognitive, or disease benefit.
|
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA Sterile Compounding Warning for NAD+ | 2024 | FDA warned compounders that food-grade NAD+ is not suitable for sterile compounding without appropriate processing because of microbial and endotoxin risk. FDA received reports after NAD+ injectable products of severe chills, shaking, vomiting, and fatigue, with some patients requiring medical treatment; FDA stated these reactions were consistent with excessive endotoxin levels. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| NAD+ Anti-aging and Wellness Evidence (2026 Review) | 2026 | 2026 review of NAD+ anti-aging and wellness evidence. Human trials show NR and NMN can increase measured NAD-related metabolites under some conditions, but clinical outcome benefits are inconsistent; evidence for a precursor cannot be transferred automatically to direct NAD+ injection. | |||
| Systematic review of NAD/NADH supplementation | 2023 | Systematic review | Human supplementation studies — Evaluates safety and effectiveness of NAD+ and NADH as supplements in humans. | Secondary source; useful for context but not a substitute for primary study review. | |
| Role of NAD+ in regenerative medicine | 2022 | Review | NAD+ biology/aging pathways — Summarizes NAD+ roles in cellular metabolism and aging-related pathways. | Secondary source; useful for context but not a substitute for primary study review. | |
| Clinical evidence for targeting NAD therapeutically | 2020 | Review | Human clinical evidence overview — Reviews clinical NAD+ pharmacology evidence and limitations. | Secondary source; useful for context but not a substitute for primary study review. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
This page separates NAD+'s essential cellular biology from unproven wellness, anti-aging, detox, or energy claims.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Website/CMS content draft; source verification and legal/privacy review required before public launch. Last updated 2026-07-08.
Follow research updates for NAD+
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.